Halozyme Therapeutics HALO Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's accrued expenses and other liabilities?
- Halozyme Therapeutics (HALO) reported accrued expenses and other liabilities of $246.82M in Q1 2026.
- How has Halozyme Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Halozyme Therapeutics's accrued expenses and other liabilities increased by 32.2% year-over-year, from $186.74M to $246.82M.
- What is the long-term trend for Halozyme Therapeutics's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's accrued expenses and other liabilities has grown at a 62.3% compound annual growth rate (CAGR), from $23.95M to $270.06M.